| Literature DB >> 27271583 |
Chia-Woei Wang1,2,3, Cheng-Jeng Tai4,5, Chen-Yen Choong6, Yu-Chun Lin7, Bao-Hong Lee8, Yeu-Ching Shi9, Chen-Jei Tai10,11,12.
Abstract
Chemotherapy, a major approach was used in carcinoma treatment, always involves the development of drug resistance as well as side-effects that affect the quality of patients' lives. An association between epithelial-mesenchymal transition (EMT) and chemotherapy resistance was established recently. We demonstrate in this paper that the aqueous extract of Paris polyphylla (AEPP)-a traditional Chinese medicine-can be used in various cancer types for suppression of carcinogenesis. We evaluated the suppressions of EMT and mitochondrial activity by AEPP treatment in a high-glucose (HG) induced-human ovarian carcinoma cell line (OVCAR-3 cells). The mitochondrial morphology was investigated using MitoTracker Deep Red FM staining. Our results indicated that AEPP reduced the viability of OVCAR-3 cells considerably through induction of apoptosis. However, this inhibitory potential of AEPP was attenuated by HG induction in OVCAR-3 cells. The levels of estrogen-related receptor (ERR)-alpha activator and peroxisome proliferator-activated receptor-gamma coactivator (PGC)-1alpha were elevated by HG induction, but were suppressed by AEPP treatment. Down-regulations of cell survival and EMT were oberved in OVCAR-3 cells through suppression of PGC-1alpha by AEPP treatment. These results were confirmed through PGC-1alpha knockdown and overexpression in OVCAR-3 cells. Thus, AEPP can be beneficial for treating ovarian cancer and has potential for development of an integrative cancer therapy against ovarian cancer proliferation, metastasis, and migration.Entities:
Keywords: Paris polyphylla; epithelial-mesenchymal transition (EMT); high glucose induction; ovarian cancer; peroxisome proliferator-activated receptor-gamma coactivator (PGC)-1alpha
Mesh:
Substances:
Year: 2016 PMID: 27271583 PMCID: PMC6273164 DOI: 10.3390/molecules21060727
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The anti-ovarian carcinoma cells activity of AEPP in OVCAR-3 cells by (A) cell viability and (B) apoptosis/necrosis measurements. Data were shown as mean ± SD (n = 3). A significant difference is shown by different letters between groups (p < 0.05).
Effects of AEPP on apoptosis induction in OVCAR-3 cells.
| Group | Surviving Cells | Early Apoptosis | Late Apoptosis | Necrosis |
|---|---|---|---|---|
| Blank | 88.83 ± 2.14 a | 7.53 ± 0.84 a | 2.41 ± 0.42 d | 1.23 ± 0.08 c |
| 5 μg/mL | 75.20 ± 1.32 ab | 4.14 ± 0.73 b | 19.33 ± 1.24 c | 1.33 ± 0.11 c |
| 25 μg/mL | 62.01 ± 1.75 b | 4.89 ± 0.49 b | 24.64 ± 1.01 bc | 8.46 ± 0.46 b |
| 50 μg/mL | 56.80 ± 1.04 c | 4.18 ± 0.67 b | 29.49 ± 1.48 b | 9.53 ± 0.58 b |
| 100 μg/mL | 38.72 ± 1.94 d | 2.87 ± 0.58 c | 48.52 ± 1.22 a | 9.89 ± 0.55 b |
| 200 μg/mL | 31.23 ± 1.27 d | 2.91 ± 0.52 c | 50.03 ± 1.45 a | 15.83 ± 0.51 a |
Data were shown as mean ± SD (n = 3). A significant difference is shown by different letters in each column (p < 0.05).
Figure 2The suppression of AEPP on OVCAR-3 ovarian carcinoma cells induced by high glucose (HG). Data were shown as mean ± SD (n = 3). Different letters indicate a significant difference between groups (p < 0.05).
Figure 3Observation of mitochondrial fission and fusion in OVCAR-3 carcinoma cells treated by (A) high glucose (HG) induction for 48 h and 72 h; or (B) HG induction with AEPP for 24 h. Fission: mitochondrial fragment; Fusion: mitochondrial network.
Figure 4The effects of high glucose induction on (A) EMT markers by Western blot and (B) the results of quantity analysis in OVCAR-3 carcinoma cells. Data were shown as mean ± SD (n = 3). A significant difference between groups (p < 0.05) is shown by different letters.
Figure 5The inhibition of high-glucose-induced (A) EMT markers by Western blot and (B) the results of quantity analysis in OVCAR-3 carcinoma cells treated by AEPP for 24 h. Data were shown as mean ± SD (n = 3). A significant difference between groups in the same protein is shown by different letters (p < 0.05).
Figure 6Effects of PGC-1alpha knockdown treatment on epithelial-mesenchymal transition (EMT) markers in high glucose (HG)-induced OVCAR-3 carcinoma cells. (A) The cells were treated with PGC-1alpha siRNA for 24 h for suppressing PGC-1alpha levels in OVCAR-3 cells; (B) subsequently resulting in HG-induced EMT and (C) the results of quantity analysis was carried out. Data are shown as the mean ± SD (n = 3). Significant differences between groups for the same protein are shown by using different letters (p < 0.05).
Figure 7The effects of regulation of PGC-1alpha overexpression (similar to high glucose induction) on EMT markers in OVCAR-3 ovarian carcinoma cells. (A) The cells were treated with PGC-1alpha overexpression vector for 60 h for elevation of PGC-1alpha levels in OVCAR-3 ovarian carcinoma cells, and were subsequently treated by AEPP for (B) EMT markers, and (C) the results of quantity analysis was carried out. Data were shown as mean ± SD (n = 3). A significant difference between groups in the same protein level (p < 0.05) is shown by different letters.
Figure 8The potential of AEPP against cell proliferation and EMT of OVCAR-3 ovarian carcinoma cells.